Table 1. Evidence that support Glaucoma Screening .

Publication Date	Title	Author	Study Type	Location	# of Patients	Demographics	Funding	Statistical Results
May 20, 2019, Lancet Global Health	Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model	Tang J et al [25]	cohort	rural and urban China	Unknown	50 years, through a total of 30 1-year Markov cycles	Ulverscroft Foundation, Wenzhou Medical University Research Fund, Zheijaiang Province Health Innovation Talents Project, and Wenzhou's Ten Major Livelihood Issues 2015	Rural screening for PACG & POAG: ICER $1280 95% ci, -58-7940; ICUR $569, 95% CI 17 to 4180, screening would prevent 246 years of blindness for every 100,000 rural residents screened and 1325 years for every 100,000 urban residents screened; thus due to increased prevalence, population screening appears cost-effective
April 2018, American Journal of Ophthalmology	Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study	Zhao D et al [26]	cross-sectional	Baltimore, MD	Phase 1: 686 (55%); Phase 2: 199 (63.8%); Overall: 885 (57.0%)	Age 50-plus, 91.2% African-American; 2.3% Hispanic	Centres for Disease Control and Prevention Vision Health Initiative grant	Phase 1 involved testing and refining the screening algorithm and implementing standard referral procedures; in Phase 2, the refined algorithm was adopted, screening venues were expanded; new strategies to maximize attendance at the referral exam were developed and evaluated, including providing a voucher that stated the value of the free eye exam, scheduling follow-up appointments within four weeks, showing testimonial videos on glaucoma's impact and follow-up procedure videos; Concluded that those at high risk should be made aware of the importance of screening despite a lack of symptoms
August 2017, American Journal of Ophthalmology	Optimizing Glaucoma Screening in High-Risk Population: Design and 1-Year Findings of the Screening to Prevent (SToP) Glaucoma Study	Zhao D et al [24]	prospective	Baltimore, MD	901	Age 50-plus, 94.9% African-American	Centres for Disease Control and Prevention Vision Health Initiative grant	Community-based screening intervention of underserved, high-risk population results: 39.5% referred for definitive ey exam; 43% attended the scheduled exam; 51% diagnosed with glaucoma
August 2017, Cogent Medicine	Screening for Glaucoma in Populations at High Risk: The eye Screening New York Project	Al-Aswad LA et al [8]	cross-sectional	northern Manhattan, NY	8,547	Age 20-plus, low socioeconomic status, 16.54% African-Americans, 54.37% Hispanic, 14.59% white	The Friends of the Congressional Glaucoma Caucus Foundation and Research to Prevent Blindness	25% referred for glaucoma evaluation; African-Americans and Hispanics 75% more likely than whites to need a referral
March 2012, Arch Ophthalmol 130(3): 365-372	Projected Outcomes of Glaucoma Screening in African-American Individuals	Ladapo JA et al [9]	microsimulation using data from the Eye Diseases Prevalence Research Group and Baltimore Eye Study	US	unknown	Age 50-59, African-American	Research to Prevent Blindness and National Institutes fo Health	The prevalence of undiagnosed glaucoma would be lowest at 19% among 50 and 59-year-olds and increase to 40% in those over age 80. If glaucoma screening reduced vision loss by 6% to 7% a year, it could save $10 million-plus in medical costs alone.
June 2004, Ophthalmol 111:1121-1131	The Los Angeles Latino Eye Study: design, methods and baseline data	Varma et al [12]	cross-sectional	La Puente, Los Angeles, CA	6,357	Age 40-plus, Latino, 58% female	National Eye Institute, National Center on Minority Health and the Health Disparities of the National Institutes of Health	4.7% OAG diagnosed
December 2001, Ophthalmol 119	The Prevalence of Glaucoma in a Population-Based Study of Hispanic Subjects	Quigley HA et al [11]	cross-sectional	Nogales and Tucson, AZ	4,774	Age 40-plus, Latino	Public Health Service Research, National Eye Institute, National Institutes of Health	0.50% age 41-49; 0.59% age 50-59; 1.73% age 60-69; 5.66% age 70-79; 12.02% age 80-89; 20.00 age 90 and up